Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance
title

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits

 

escrs app advert yo advert

Posters

Search Title by author or title

Posterior iris-claw to correct aphakia in the absence of capsule support: visual outcome and complications

Poster Details

First Author: A. Baba TUNISIA

Co Author(s):    W. Zbiba   E. Bouayed   N. Ben Abdessalem   M. lahdiri           

Abstract Details

Purpose:

determinate the Visualoutcome and complications of Posterior iris-claw to correct aphakia in the absence of capsule support.

Setting:

Correction of aphakia in the absence of capsule support can be achieved by several techniques of IOL implantation. Introduced since 40 years, iris-claw aphakic intraocular lens implantation is one of these methods

Methods:

This retrospective case series comprised patients who had implantation of an Artisan iris-claw IOL at the department of ophthalmology in the University Hospital of Nabeul in Tunisia from 2011 to 2015 because of a lack of posterior capsule support. we evaluated the indications, visualoutcomes, and safety of iris-claw IOL implantation for aphakia. The mean Follw-up was 10 months (3 to 18 months)

Results:

The study comprised 60 eyes. The IOLs were inserted during primary lens surgery in 20 eyes (33.4%), during an IOL exchange procedure for IOP elevation after AC IOLs in 8 eyes (13.4%), and as a secondary procedure in 32 eyes (53.2%). The median final corrected distance visual acuity was 4/10. Forty one eyes (68.4%) had a final corrected distance visual acuity of 5/10 or better. Complications included slight temporary pupil ovalization in 4 eyes (6.67%), cystoid macular edema in 4 eyes (6.67%), and elevated intraocular pressure in 7 eyes (11.7%). No case of endophthalmitis or Iris-claw IOL disenclavation was occurred.

Conclusions:

iris-claw IOL implantation for aphakia gave a good visual outcome with a favorable complication rate and can be used for a wide range of indications in eyes without adequate capsule support

Financial Disclosure:

NONE

Back to Poster listing